Evidence map›Paper›PMID 10209035›Full record

ArticleThe Journal of experimental medicine1999

Hapten-induced colitis is associated with colonic patch hypertrophy and T helper cell 2-type responses.

T Dohi, K Fujihashi, P D Rennert, K Iwatani, H Kiyono, J R McGhee

Open access · bronzeAbstract read
In one paragraph

Article in The Journal of experimental medicine, 1999. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 57 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
57citing papers in PubMed, 1 pooled it
4.7field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

57 citing papers in PubMed, 1 synthesis or guideline pooled it, 177 citations in OpenAlex.

  1. Pooled it
  2. Mucosal Responses to Type II Interferon in IBD.Inflammatory bowel diseases · 2025
    Article
  3. Article
  4. Human intestinal B cells in inflammatory diseases.Nature reviews. Gastroenterology & hepatology · 2023
    Review
  5. Article
  6. Review
  7. Lactobacillus plantarum strains attenuated DSS-induced colitis in mice by modulating the gut microbiota and immune response.International microbiology : the official journal of the Spanish Society for Microbiology · 2022
    Article
  8. Review
  9. Review
  10. Article
  11. Review
  12. Article
  13. Article
  14. Novel anti-inflammatory agent 3-[(dodecylthiocarbonyl)-methyl]-glutarimide ameliorates murine models of inflammatory bowel disease.Inflammation research : official journal of the European Histamine Research Society ... [et al.] · 2016
    Article
  15. Experimental Models of Inflammatory Bowel Diseases.Cellular and molecular gastroenterology and hepatology · 2015
    Article
  16. Article
  17. The Mechanisms of M-cell Differentiation.Bioscience of microbiota, food and health · 2014
    Review
  18. Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 3 institutions in 2 countries.

T DohiImmunobiology Vaccine Center, Department of Microbiology, University of Alabama at Birmingham, Alabama, USA.
K Fujihashi
P D Rennert
K Iwatani
H Kiyono
J R McGhee
Biogen (United States) · USOsaka University · JPUniversity of Alabama at Birmingham · US

Funding

MOLECULAR ADJUVANTS FOR NALT-BASED IMMUNITY TO ANTHRAXR01AI043197 · NIAID · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI BOYAKA, PROSPER N · 1998 to 2013
$4.6M
TH2 CELLS DIRECT THE GENESIS OF COLONIC PATCHES AND IBDP01DK044240 · NIDDK · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI ELSON, CHARLES O · 1991 to 2003
$3.2M
A ROLE FOR INNATE IMMUNITY IN SALIVARY IgA RESPONSESR01DE012242 · NIDCR · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI FUJIHASHI, KOHTARO · 2002 to 2010
$2.9M
CELLULAR AND MOLECULAR MECHANISMS FOR MUCOSAL IMMUNITYR01AI018958 · NIAID · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI FUJIHASHI, KOHTARO · 1985 to 2005
$1.6M
REGULATION OF ANTIGEN SPECIFIC SALIVARY IMMUNE RESPONSESR29DE012242 · NIDCR · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI FUJIHASHI, KOHTARO · 1997 to 2001
$214k
NIAID NIH HHS AI 18958NIAID NIH HHS AI 43197NIAID NIH HHS R01 AI018958NIAID NIH HHS R01 AI043197NIDCR NIH HHS R01 DE012242NIDCR NIH HHS R29 DE012242NIDDK NIH HHS DK 44240NIDDK NIH HHS P01 DK044240
6 · The paper itself

Abstract

To investigate the potential involvement of T helper (Th)2-type responses in murine models of intestinal inflammation, we used trinitrobenzene sulfonic acid (TNBS)-hapten to induce inflammatory bowel disease in situations where Th1-type responses with interferon (IFN)-gamma synthesis are either diminished or do not occur. Intracolonic administration of TNBS to either normal (IFN-gamma+/+) or Th1-deficient IFN-gamma knockout (IFN-gamma-/-) BALB/c mice resulted in significant colitis. In IFN-gamma-/- mice, crypt inflammation was more severe than in IFN-gamma+/+ mice and was accompanied by hypertrophy of colonic patches with a lymphoepithelium containing M cells and distinct B and T cell zones resembling Peyer's patches. Hapten-specific, colonic patch T cells from both mouse groups exhibited a Th2 phenotype with interleukin (IL)-4 and IL-5 production. TNBS colitis in normal mice treated with anti-IL-4 antibodies or in IL-4(-/-) mice was less severe than in either IFN-gamma+/+ or IFN-gamma-/- mice. Our findings now show that the Th2-type responses in TNBS colitis are associated with colonic patch enlargement and inflammation of the mucosal layer and may represent a model for ulcerative colitis.

Indexed as

AnimalsAntibodiesColitis, UlcerativeColonDisease Models, AnimalHaptensHypertrophyInflammatory Bowel DiseasesInterferon-gammaInterleukin-4Interleukin-5MiceMice, Inbred BALB CMice, KnockoutPeyer's PatchesTh1 CellsAntibodiesHaptensInterferon-gammaInterleukin-4Interleukin-5Trinitrobenzenesulfonic Acid

Identifiers

PMID10209035
PMCPMC2193023
OpenAlexW2001835390

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-SA
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.